HCV-ASSOCIATED LIVER CIRRHOSIS: MODERN POSSIBILITIES OF INTERFERON-FREE THERAPY (ACCORDING TO THE RESULTS OF PROGRAM OF EARLY ACCESS)


I.G. Bakulin (1), D.T. Abdurakhmanov (2, 3), N.V. Shalikiani (1), A.V. Polukhina (1), Yu.A. Matveeva (1), E.I. Sidorova (3), T.P. Rozina (2), E.N. Nikulkina (2)

(1) SBHCI "Moscow Clinical Research Center" of Moscow Healthcare Department; (2) SBEI HPE "First MSMU n.a.I.M.Sechenov" of RMPH, Moscow; (3) MSU n.a. M.I. Lomonosov, Moscow
The article presents theresults of studies of combination therapy using antiviral drugs with direct action as follows: daklatasvir 60 mg 1 time a day plus asunaprevir 100 mg twice a day for 24 weeks with the participation of 29 cirrhotic patients with 1b HCV genotype. It was shown that the use of interferon-free combination asunaprevir + daklatasvir allows to consider it as a safe and effective scheme of choice in patients with HCV-associated liver cirrhosis.

Literature


  1. Guidelines for the screening, care and treat-ment of persons with hepatitis c infection. WHO. 2014.
  2. EASL Recommendations on Treatment of Hepatitis C. 2015.
  3. Бакулин И.Г., Галушко М.Ю. Противови-русная терапия хронического гепатита С: состояние вопроса. http://www.hcv.ru/articles/stat/me-pvt.html.
  4. Абдурахманов Д.Т., Морозов В.Г. Безо-пасность и эффективность телапревира в лечении хронического гепатита С у больных российской популяции, включенных в исследование по программе раннего доступа. РЖГГК. 2014;24(1):39–46.
  5. Manns M., Pol M., Jacobson I.M., et al. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet 2014;384( 9954):1597–605.
  6. Kao J-H., Heo J., Yoffe B.,Sievert W., Jacobson I.M., Bessone F., Peng C-Y., Roberts S., Yoon K.T., Kopit J., Linaberry M., Noviello S., Hughes E., Manns M. Efficacy and safety of daclatasvir in combination with asunaprevir (DCV+ASV) in cirrhotic and non-cirrhotic patients with HCV genotype 1B: results of the the HALLMARK DUAL study. J. Hepatol. 2014;60(Suppl.):P1300.
  7. Kumada H., Suzuki Y., Ikeda K., Toyota J., Karino Y., Chayama K., Kawakami Y., Ido A., Yamamoto K., Takaguchi K., Izumi N., Koike K., Takehara T., Kawada N., Sata M., Miyagoshi H., Eley T., McPhee F., Damokosh A., Ishikawa H., Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59(6):2083–91.
  8. Wei L., Zhang M.Х., еt al. Daclatasvir and Asunaprevir in Non-Japanese Asian Patients with Chronic HCV Genotype 1b Infection who are Ineligible for or Intolerant to Interferon-alfa Therapies With or Without Ribavirin: Phase 2015;3 SVR12 Interim Results. ASLD.


About the Autors


I.G. Bakulin – Doctor of Medical Scineces, Prof., Head of the Department of Hepatology SBHCI "Moscow Clinical Research and Practical Center " of Moscow Healthcare Department; Head of the Medical Institute of Postgraduate Education of Physicians MSUFD, Moscow; e-mail: igbakulin@yandex.ru


Similar Articles


Бионика Медиа